Upperton Pharma Solutions - Drug Development and Delivery

Upperton Pharma Solutions
Trent Gateway, Technology Drive, Beeston, Nottingham, NG9 1LA
UNITED KINGDOM
Visit Our Website
Visit Our Linkedin
Contact Us

Company Description

Upperton is a UK-based CDMO providing integrated contract development and manufacturing services. Specialising in oral, nasal, pulmonary and sterile dosage forms, Upperton offers a comprehensive range of services designed to support the progression of a molecule from early feasibility through to formulation development, clinical trial manufacture and commercial manufacture.

With over 25 years of experience, Upperton excels in rapid product introductions.

Our project delivery is unparalleled and designed specifically to align with the
values and innovation of small to mid-sized pharma companies.
We are flexible and nimble, enabling rapid decision-making, problem-solving, collaboration, and product introduction within 4-6 weeks.
With subject matter experts and leadership team oversight on every project, you can trust our project delivery and expertise covers all layers of our operations.
For small molecules and biologics, our clinical manufacturing process trains support batch sizes from grams to kilograms.

Integrated CDMO Services

Experts in Oral, Nasal, Pulmonary & Sterile Dosage Forms

Upperton offers expertise in developing a range of small molecule and biologics dosage forms, providing support from early feasibility studies through to clinical and commercial manufacture.

Oral Solids: Upperton specialises in the development of both simple and complex oral dosage forms, including powders, capsules, and tablets (IR, MR, SR, Minitabs)
Nasal: Supporting both liquid and dry powder formulation, the development platform, UpperNose™, streamlines and accelerates the process of developing nasal dosage forms for clinical trial studies.
Pulmonary: Through expertise in formulation development, particle engineering and device selection. Upperton offers both dry powder and liquid formulation options, addressing factors such as solubility, stability, and target dose delivery into the lungs.
Sterile: Our team can support you with aseptic and terminally sterilized small volume liquids and powders for parenteral, nasal and pulmonary delivery.

Our Manufacturing Capabilities at a Glance

Up to 1,000,000 tableting capacity per day
500g – 205kg blending capacity
Up to 2,000 blister packaging units per day
Up to 50kg tablet coating per batch
Up to 350,000 capsule filling (powder) capacity per day
Up to 1000kg dry granulation capacity per day
0.5g – 10kg spray drying batch sizes (aqueous and solvent)
20 litres solution preparation vessels capacity with overhead mixing
10 state-of-the-art GMP manufacturing suites

Our Approach to Project Delivery

Upperton tailors projects to fit specific client timelines and requirements, prioritizing effective communication and collaboration in project delivery. Each project is assigned a project manager who coordinates all activities and ensures that transparency is maintained through regular updates.

Project teams at Upperton are composed of experts from various disciplines, including development, GMP, analytical, QA, and technical transfer. The inclusion of an Executive Leadership Team member in every project, ensures that decisions are made under expert guidance.

Upperton Pharma Solutions (Upperton) Wins Integrated Manufacturing Award at the 2025 Pharmaceutical Technology Excellence Awards.

Upperton, UK-based CDMO (Contract, Development & Manufacturing Organization) recognized as winner in the Integrated Manufacturing (Business Expansion) category at the 2025 Pharmaceutical Technology Excellence Awards.
Award follows the build of a 50,000 sq. ft development and manufacturing facility for oral, nasal and pulmonary dosage forms, alongside a 7,000 sq. ft sterile manufacturing facility built against revised EU GMP Annex-1 regulations.
CEO, Nikki Whitfield said: “Being recognized as an Excellence Award winner is a great achievement and highlights the hard work of all of our team over the past few years. This award recognizes the vision we had when embarking on a new facility, and expansion into sterile manufacturing”.

Explore Our Resources

The New Rules of CDMO Partnerships: What Biotechs Should Be Looking for Next

Videos

Discover Our Integrated CDMO Services

Whitepapers

Pharmaceutical Spray Drying: Technology & Applications

Transitioning Your Product from Phase 1 To Phase 2 Clinical Studies

Nose To Brain (N2B) Drug Delivery – Benefits & Challenges

Nasal Delivery of Spray Dried Biologics: Opportunities & Challenges

Spray Drying Biologics: An Alternative to Freeze Drying

In Vivo Testing of Nasal Dosage Forms

A Thermofluor Screen for Rational Buffer Optimisation

Soft Midst Inhalers: Lung Deposition Benefits for Respiratory Conditions